Ica 200mg Capsule contains Itraconazole 200mg, a broad-spectrum antifungal agent belonging to the triazole class. It is indicated for the treatment of various systemic and superficial fungal infections, including aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis. Itraconazole exerts its antifungal effect by inhibiting the cytochrome P450-dependent enzyme lanosterol 14-α-demethylase, which is essential for the synthesis of ergosterol, a critical component of fungal cell membranes. This inhibition disrupts membrane integrity, leading to increased cellular permeability and ultimately fungal cell death. Ica 200mg Capsule is administered orally and demonstrates good bioavailability, with enhanced absorption when taken with food. It is metabolized primarily by the liver via the cytochrome P450 system and has a half-life of approximately 24-42 hours. Caution is advised in patients with hepatic impairment, congestive heart failure, or those taking medications that may interact with itraconazole, such as certain statins, benzodiazepines, and calcium channel blockers, due to the risk of adverse effects and drug interactions. Common side effects include gastrointestinal disturbances, headache, and rash. Ica 200mg Capsule should be used under medical supervision with appropriate monitoring of liver function and clinical response.